We detected serum AFP-IgM levels in patients with primary hepatocellular carcinoma in Kazakh and Han populations to investigate the clinical significance of AFP-IgM in the diagnosis of hepatocellular carcinoma.
Methods and study design
Serum AFP-IgM levels were examined in 28 cases of hepatocellular carcinoma and 164 controls in the Kazakh population and in 85 cases of hepatocellular carcinoma and 187 controls in the Han population. AFP-IgM was detected with the ELISA assay.
Results
In general, serum AFP-IgM levels of hepatocellular carcinoma patients in the Han population and hepatocellular carcinoma patients in the Kazakh population were statistically higher than those of controls, but there was no statistical significance between hepatocellular carcinoma patients in the Han and hepatocellular carcinoma patients in the Kazakh population.
Conclusions
AFP-IgM is an encouraging serological marker and may be useful in the diagnosis of hepatocellular carcinoma.
JemalA., SiegelR., XuJ., WardE.: Cancer statistics, 2010.CA Cancer J Clin, 60: 277–300, 2010.
2.
ParkinD.M., BrayF., FerlayJ., PisaniP.: Global cancer statistics, 2002.CA Cancer J Clin, 55: 74–108, 2005.
3.
ZhangS., LiL., LuF.: Mortality of primary liver cancer in China from 1990 through 1992 [in Chinese].Zhonghua Zhong Liu Za Zhi, 21: 245–249, 1999.
4.
OmataM., YoshidaH.: Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C.Scand J Gastroenterol Suppl, 47–51, 2003.
5.
ShiJ., ZhuL., LiuS., XieW.F.: A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.Br J Cancer, 92: 607–612, 2005.
6.
VibertE., AzoulayD., HotiE., IacopinelliS., SamuelD., SalloumC., LemoineA., BismuthH., CastaingD., AdamR.: Progression of alpha-fetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor.Am J Transplant, 10: 129–137, 2010.
7.
ShuH., KangX., GuoK., LiS., LiM., SunL., GanL., LiuY., QinX.: Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to alpha fetoprotein.Oncol Rep, 24: 1271–1276, 2010.
8.
SoresiM., MagliarisiC., CampagnaP., LetoG., BonfissutoG., RiiliA., CarroccioA., SestiR., TripiS., MontaltoG.: Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma.Anticancer Res, 23: 1747–1753, 2003.
9.
TongM.J., BlattL.M., KaoV.W.: Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.J Gastroenterol Hepatol, 16: 553–559, 2001.
10.
BeneduceL., CastaldiF., MarinoM., TonoN., GattaA., PontissoP., FassinaG.: Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes.Int J Biol Markers, 19: 155–159, 2004.
11.
GiannelliG., FransveaE., TrerotoliP., BeaugrandM., MarinosciF., LupoL., NkontchouG., DenticoP., AntonaciS.: Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients.Clin Chim Acta, 383: 147–152, 2007.
12.
ShengS.L., WangQ., HuangG., YuB., QinW.X.: Simultaneous determination of alpha-fetoprotein immune complexes and alpha-fetoprotein concentration in hepatocellular carcinoma using dual-label time-resolved immunofluorometric assays.J Clin Lab Anal, 23: 179–185, 2009.
13.
JingtingJ., ChangpingW., NingX., YibeiZ., JunW., MeiJ., BinX., PeterN.E., XueguanZ.: Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma.J Clin Lab Anal, 23: 213–218, 2009.
14.
JiangJ., WuC., ShenY., XuB., ZhengX., LiX., XuN.: Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma.Anticancer Res, 31: 687–691, 2011.
15.
QukuerhanA., XaymardanX.: The epidemiological analysis of 904 cases of malignant tumor of Kazak in Xinjiang [in Chinese].Tumor, 23: 11–13, 2003.
16.
BruixJ., ShermanM., LlovetJ.M., BeaugrandM., LencioniR., BurroughsA.K., ChristensenE., PagliaroL., ColomboM., RodésJ; EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.J Hepatol, 35: 421–430, 2001.
17.
BeneduceL., CastaldiF., MarinoM., QuartaS., RuvolettoM., BenvegnùL., CalabreseF., GattaA., PontissoP., FassinaG.: Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.Cancer, 103: 2558–2565, 2005.
BerezinaG., SvyatovaG., MakhmutovaZ.: The analysis of the genetic structure of the Kazakh population as estimated from mitochondrial DNA polymorphism.Med Health Sci J, 6: 2–6, 2011.
